Grace Hampson : Citation Profile


Are you Grace Hampson?

Office of Health Economics

3

H index

1

i10 index

30

Citations

RESEARCH PRODUCTION:

6

Articles

19

Papers

RESEARCH ACTIVITY:

   6 years (2015 - 2021). See details.
   Cites by year: 5
   Journals where Grace Hampson has often published
   Relations with other researchers
   Recent citing documents: 10.    Total self citations: 5 (14.29 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pha1219
   Updated: 2022-09-24    RAS profile: 2021-07-12    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers


Works with:

Towse, Adrian (8)

Devlin, Nancy (3)

Mott, David (2)

Berdud, Mikel (2)

Authors registered in RePEc who have co-authored more than one work in the last five years with Grace Hampson.

Is cited by:

Shah, Koonal (2)

Graf von der Schulenburg, Johann (2)

Lorgelly, Paula (1)

Cites to:

Towse, Adrian (9)

Lancsar, Emily (5)

Devlin, Nancy (4)

Shah, Koonal (4)

Baltagi, Badi (3)

Hole, Arne (3)

Moscone, Francesco (3)

Tsuchiya, Aki (3)

Cole, Amanda (3)

He, Xuezhong (Tony) (2)

Garau, Martina (2)

Main data


Where Grace Hampson has published?


Journals with more than one article published# docs
Applied Health Economics and Health Policy3

Working Papers Series with more than one paper published# docs
Research Papers / Office of Health Economics8
Consulting Reports / Office of Health Economics7
Briefings / Office of Health Economics4

Recent works citing Grace Hampson (2022 and 2021)


YearTitle of citing document
2021Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe. (2021). Chambers, James D ; Persson, Ulf ; Malone, Daniel C ; Sullivan, Sean D ; Fricke, Frank-Ulrich ; Drummond, Michael ; Dabbous, Omar ; Toumi, Mondher ; Neumann, Peter J ; Hanna, Eve ; Tunis, Sean. In: Health Policy. RePEc:eee:hepoli:v:125:y:2021:i:12:p:1550-1556.

Full description at Econpapers || Download paper

2021The Role of Patient Experience in the Value Assessment of Complex Technologies – Do HTA Bodies Need to Reconsider How Value is Assessed?. (2021). Upadhyaya, Sheela ; Kalo, Zoltan ; Bertelsen, Neil ; Brixner, Diana ; Mountian, Irina ; Szegvari, Boglarka ; Freitag, Andreas ; Sarri, Grammati. In: Health Policy. RePEc:eee:hepoli:v:125:y:2021:i:5:p:593-601.

Full description at Econpapers || Download paper

2022Promoting innovation while controlling cost: The UKs approach to health technology assessment. (2022). Mossialos, Elias ; Carter, Paul ; McGuire, Alistair ; Taylor, David ; Drummond, Michael ; Anderson, Michael. In: Health Policy. RePEc:eee:hepoli:v:126:y:2022:i:3:p:224-233.

Full description at Econpapers || Download paper

2021Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries. (2021). Francois, Clement ; Wang, Yitong ; Qiu, Tingting ; Toumi, Mondher ; Zhou, Junwen. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:19:y:2021:i:3:d:10.1007_s40258-020-00634-0.

Full description at Econpapers || Download paper

2022Value-based pricing for advanced therapy medicinal products: emerging affordability solutions. (2022). Gonalves, Elisabete. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:23:y:2022:i:2:d:10.1007_s10198-021-01276-2.

Full description at Econpapers || Download paper

2021Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment. (2021). Bouvy, Jacoline C ; Rijnbeek, Peter ; Hughes, Nigel ; Ostby, Jens Torup ; Jonsson, Pall ; Dawoud, Dalia ; Burn, Edward ; Kent, Seamus. In: PharmacoEconomics. RePEc:spr:pharme:v:39:y:2021:i:3:d:10.1007_s40273-020-00981-9.

Full description at Econpapers || Download paper

2021Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision. (2021). Kanters, Tim A ; Schouten, Jan L ; Vegter, Stefan ; Versteegh, Matthijs M ; Huygens, Simone A. In: PharmacoEconomics. RePEc:spr:pharme:v:39:y:2021:i:4:d:10.1007_s40273-021-01003-y.

Full description at Econpapers || Download paper

2021Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine. (2021). Versteegh, Matthijs ; Huygens, Simone ; Vellekoop, Heleen ; Molken, Maureen Rutten-Van ; Wordsworth, Sarah ; Tsiachristas, Apostolos ; Koleva-Kolarova, Rositsa ; Nagy, Balazs ; Zelei, Tamas ; Szilberhorn, Laszlo. In: PharmacoEconomics. RePEc:spr:pharme:v:39:y:2021:i:7:d:10.1007_s40273-021-01010-z.

Full description at Econpapers || Download paper

2021Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review. (2021). Borle, Kennedy ; Ho, Joseph Khoa ; Lynd, Larry D ; Ross, Colin ; Kopac, Nicola ; Kitchin, Vanessa ; Dhillon, Manrubby ; Dragojlovic, Nick. In: PharmacoEconomics. RePEc:spr:pharme:v:39:y:2021:i:9:d:10.1007_s40273-021-01051-4.

Full description at Econpapers || Download paper

2021Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions. (2021). Ferguson, Gary T ; Roberts, Melissa H. In: PharmacoEconomics - Open. RePEc:spr:pharmo:v:5:y:2021:i:1:d:10.1007_s41669-020-00221-y.

Full description at Econpapers || Download paper

Works by Grace Hampson:


YearTitleTypeCited
2016New Age Decision Making in HTA: Is It Applicable in Asia? In: Briefings.
[Full Text][Citation analysis]
paper0
2017Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies In: Briefings.
[Full Text][Citation analysis]
paper1
2017How can HTA meet the needs of health system and government decision makers? In: Briefings.
[Full Text][Citation analysis]
paper0
2017Transferability of HTA In: Briefings.
[Full Text][Citation analysis]
paper0
2016Four Case Studies to Explore the Added Value of Oxford AHSN In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2017Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose? In: Consulting Reports.
[Full Text][Citation analysis]
paper1
2017Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market In: Consulting Reports.
[Full Text][Citation analysis]
paper1
2019Public Preferences for Health Gains and Cures: A Discrete Choice Experiment In: Consulting Reports.
[Full Text][Citation analysis]
paper1
2020Opportunities to Increase Efficiency in Healthcare In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2021Exploring the Financial Sustainability of Gene Therapies In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2021Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2015Dementia: The R&D Landscape In: Research Papers.
[Full Text][Citation analysis]
paper0
2016A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications In: Research Papers.
[Full Text][Citation analysis]
paper3
2016Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) In: Research Papers.
[Full Text][Citation analysis]
paper0
2018Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).(2018) In: PharmacoEconomics - Open.
[Full Text][Citation analysis]
This paper has another version. Agregated cites: 0
article
2017Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value In: Research Papers.
[Full Text][Citation analysis]
paper2
2017Macro Evaluation of the NIHR Oxford Biomedical Research Centre In: Research Papers.
[Full Text][Citation analysis]
paper0
2018Real World Evidence for Coverage Decisions: Opportunities and Challenges In: Research Papers.
[Full Text][Citation analysis]
paper6
2018Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions In: Research Papers.
[Full Text][Citation analysis]
paper0
2019HTA and Payment Mechanisms for New Drugs to Tackle AMR In: Research Papers.
[Full Text][Citation analysis]
paper0
2017What Determines the Health Care Expenditure of High Income Countries? A Dynamic Estimation In: Applied Economics and Finance.
[Full Text][Citation analysis]
article0
2017A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact? In: Applied Health Economics and Health Policy.
[Full Text][Citation analysis]
article3
2020A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance In: Applied Health Economics and Health Policy.
[Full Text][Citation analysis]
article1
2020Authors’ Reply to Hays: “A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance” In: Applied Health Economics and Health Policy.
[Full Text][Citation analysis]
article0
2019Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article11

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated August, 1st 2022. Contact: CitEc Team